Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Print this page Email this page Users Online: 105
ORIGINAL ARTICLE
Year : 2020  |  Volume : 13  |  Issue : 5  |  Page : 437-440

Our experience with stroke thrombolysis at a tertiary care center in South India


1 Department of Neurology, Kakatiya Medical College and MGM Hospital, Warangal, Telangana, India
2 Department of Medicine, Kakatiya Medical College and MGM Hospital, Warangal, Telangana, India

Correspondence Address:
Veeramalla Madhavarao
Department of Neurology, Kakatiya Medical College and MGM Hospital, Warangal, Telangana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mjdrdypu.mjdrdypu_181_19

Rights and Permissions

Introduction: Intravenous (IV) thrombolysis is the cornerstone of the treatment of acute ischemic stroke in modern stroke era. Alteplase, also known as recombinant tissue plasminogen activator, is currently the only approved drug for IV thrombolysis worldwide and is used for the treatment of acute ischemic stroke. Objective: The objective was to study the clinical efficacy and safety of IV thrombolysis with alteplase in acute ischemic stroke. Materials and Methods: We consecutively enrolled acute ischemic stroke patients who underwent IV thrombolysis with alteplase from October 2017 to May 2018. Primary clinical efficacy outcome was defined as an improvement in the National Institute of Health Stroke Scale (NIHSS) score of ≥4 points at 24 h. The secondary clinical efficacy outcome was the favorable outcome on the modified Rankin scale at 90 days, which is defined as a score of 0 or 1. The safety endpoints were death rate at 90 days and symptomatic intracranial hemorrhage (SICH). Results: The mean NIHSS scores at baseline and 24 h were 13.56 (±4.56) and 9.92 (±6.13), respectively, the difference being statistically significant (P < 0.001). In this study, 15 patients (60%) met the primary clinical efficacy outcome, and the same number achieved the secondary clinical efficacy outcome. Three patients (12%) developed SICH but without any deaths. Conclusion: This study confirms the efficacy and safety of alteplase for stroke thrombolysis in our clinical setting.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed144    
    Printed8    
    Emailed0    
    PDF Downloaded40    
    Comments [Add]    

Recommend this journal